104results about How to "Increase secretion level" patented technology

Methods for enhancing expression levels and secretion of heterologous fusion proteins in a host cell are disclosed.

The invention provides an NK cell in-vitro induced amplification method which comprises the following step: adding a radix tetrastigme extract into an NK cell culture solution, wherein the concentration of the radix tetrastigme extract is 0.00625-9.76 mu g/ml, and the radix tetrastigme extract is radix tetrastigme total extract Th-t, boiled desugarized part Th-w3, petroleum ether part Th-p or water part desugarized part Th-w2. According to the method, abundant NK cells with higher application safety, higher purity and higher killing activity can be obtained under in-vitro culture conditions, so that the cells achieve the quality indexes for safe and effective clinical application. The method is simple to operate, low in cost and suitable for large-scale application. The NK cells obtained by the method have obviously higher cell number, purity, killing activity and cell factor secretion level. When the method is used for culture, the cell number is enhanced by thousands of times.

The invention concerns CD40 skipping 5 nucleic acid sequences and amino acid sequences obtained by alternative splicing of CD40, pharmaceutical compositions comprising said sequences and methods for treatment of a disease, wherein a beneficial therapeutic effect is achieved by the up regulation of the CD40-R-CD40-L interaction. An antibody capable of selectively binding to the amino acid of CD40 skipping 5 and pharmaceutical composition comprising the above antibody and methods for detecting the presence of exon 5 skipping expression in a sample are also within the scope of the invention.

The invention discloses the application of astragalin in preparation of anti-ovarian-senescence medicaments. Astragalin can treat various ovarian failure diseases, and has a remarkable effect on polycystic ovarian syndrome, dysfunctional uterine bleeding, premature ovarian failure or climacteric syndrome and the like. According to the invention, astragalin is prepared into oral medicaments, percutaneous medicaments or parenteral medicaments for treating ovarian failure diseases.

The present invention relates techniques for identifying suitable secretion fusion partner (SFP) for hyper-secretory production of recombinant proteins. The SFPs can be obtained from secretome analyses. Recombinant proteins are produced in a fusion form with a secretion fusion partner (SFP) and can be separated from the SFP by in vitro protease treatment. SFPs of this invention greatly improve the secretion level of target proteins and peptides which are valuable for bio-pharmaceuticals and the bio-industry.

The invention discloses a preparation method of frozen juice containing tropical fruit mixed pulp. The preparation method comprises the following steps: grading and selecting raw fruits; washing the fruits; disinfecting the fruits with DBDMH; blanching the fruits at 90-95 DEG C for 30 seconds; peeling and dicing the blanched fruits or extracting the pulp from the blanched fruits; instantly freezing the diced fruits or pulp to minus 30 DEG C in an instant freezer; then preparing mixed pulp; mixing the mixed pulp with mixed syrup which is prepared from fructose-glucose syrup, isomaltulose syrup, composite phosphate, composite organic acid and purified water; and obtaining a finished product after inspection and subpackage. The invention has the following advantages: the nutrient components in the fruits, especially dietary fibers and vitamin C, are furthest retained, and the mouthfeel of fresh fruits is retained; and the juice has comprehensive and balanced nutrition through scientific combination, is not easy to undergo enzymatic browning, and is not easy to cause wide fluctuation of blood sugar.

The present invention relates to novel compounds of formula I and therapeutically acceptable salts thereof, their pharmaceutical compositions, processes for making them and their use as therapeutic methods for treatment and/or prevention of various diseases. In particular the invention relates to compounds, which inhibit the Aβ40 and Aβ42 production, increase the Aβ37 and Aβ38 production and maintain the Notch signaling and will be used for treatment and/or prevention of Aβ-related pathologies such as Alzheimer's disease, Downs syndrome and β-amyloid angiopathy, such as but not limited to cerebral amyloid angiopathy, hereditary cerebral hemorrhage, disorders associated with cognitive impairment, such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

The invention belongs to the technology field of Tibetan medical health food, particularly a hard capsule prepared from saffron extract, Tibetan medlar extract, Tibetan solomonseal extract, Tibetan angelica extract, Chinese yam extract, multiflower knotweed root extract, seaweed extract, proanthocyanidin , vitamin B6, vitamin E, vitamin C, etc. The prepration process for the hard capsule includes mixing the materials, stirring; filling into capsules, sealing; checking; and packaging to obtain finished product. The capsule is effective in caring ovary, caring skin, postponing aging, etc.

The invention discloses an application of catalpol in preparing ovarian aging resisting medicaments. The catalpol can treat various ovarian aging diseases, and particularly has obvious effects on polycystic ovarian syndrome, dysfunctional uterine bleeding, premature ovarian failure or menopause syndrome and the like. According to the application, the catalpol is prepared into oral medicaments, transdermal medicaments or injections for treating ovarian failure diseases.

The invention provides a human mesothelin chimeric antigen receptor and a T cell, a preparation method and use thereof. The mesothelin chimeric antigen receptor comprises an anti-mesothelin scFv antibody, a CD8 hinge region, a CD28 transmembrane region, a CD3 intracellular region and a 41BB intracellular region. Nucleic acid encoding the receptor, a vector containing the nucleic acid and a host cell comprising the vector are further provided. A method for using the vector for transducing human CD8+/CD4+ T cells to obtain the CARmesothelin-T cell is further provided. The cell is obtained by genetic modification of the T cell and can be used for treating diseases related to mesothelin expression, especially for specifically recognizing and killing mesothelin expression tumors.

The research group selects the optimum method for preparing a product of the invention, namely, enabling 100nM miR-21inhibitor transfected by lipo 2000 RNAimax to enter the stem cell. The stem cell product prepared by the method is enhanced in the capacity of secreting transforming growth factor TPF-beta 1, thus the capacity of inducing the T cell to differentiate towards regulatory T cells after co-culture of the cell and the T cell is enhanced, namely, the immunoregulation capacity of the stem cell is enhanced. In an in-vivo experiment, a medicine is adopted for inducing a mouse for establishing an acute enteritis model, the stem cell and a control cell which are transfected by miR-21 inhibitor are transfused into the body of the mouse through caudal vein by using the dosage of 1X10<6>, the result shows that the clinical symptoms and the immune indices of the mouse with stem cell group transfected by miR-21 inhibitor transfused are superior to those of the control cell group with transfusion, namely, the stem cell transfected by miR-21 inhibitor can be used for more effectively treating mouse enteritis. All in all, the stem cell with strong and stable effect is prepared, and experimental basis is provided for improving the application efficiency of the stem cell in clinic.

The invention discloses frozen juice containing passion fruit-mango mixed pulp and a preparation method thereof. The method comprises the following steps of: grading passion fruit and mango, selecting and cleaning; disinfecting with dibromohydantoin; blanching at the temperature 90-95 DEG C for 30 seconds; peeling the fruits, dicing or digging pulp; instantly freezing to 30 DEG C below zero in aninstant freezer and preparing mixed pulp; mixing the mixed pulp with mixed syrup which is prepared from high fructose syrup, isomaltulose syrup, composite phosphate, complex organic acid and purifiedwater; and inspecting and performing split charging to obtain a finished product. The invention has the advantages: nutritional ingredients of fruits, particularly dietary fiber and vitamin C are kept to the maximum extent, the mouthfeel of fresh fruits is kept, comprehensive and balanced nutrition is realized by scientific mixing, the juice undergoes enzymatic browning difficultly, and large-amplitude fluctuation of blood sugar is not caused easily.

The invention relates to a self-assembly nano adjuvant and a preparation method of a nano vaccine formed by the self-assembly nano adjuvant and application. The nano adjuvant comprises self-assembly materials of protamine sulfates and carboxymethyl glucan, the self-assembly materials and CpG oligodeoxynucleotides self-assembly form the nano adjuvant, and the nano vaccine is formed by the nano adjuvant and the virus antigen. The nano adjuvant increases the bioavailability of the CpG oligodeoxynucleotides, degradation in the body is avoided, and the B type CpG is added the function of A type CpG. The nano vaccine not only can induce the humoral immune response of TH1 type, but also induce relatively high cellular immune response. The unvaccinated experiments in mice body proves that the nanovaccine has good protection function, which provides help in the application of nano vaccine in the future.

The invention discloses a dragon tree leaf/dendrobe pharmaceutical composition, and a preparation method, preparation and application thereof, belonging to the technical field of preparation of medicines. The pharmaceutical composition comprises 45-55 parts by weight of dragon tree leaf ultrafine powder and 45-55 parts by weight of dendrobe ultrafine powder. The preparation method comprises the following steps: removing impurities from dragon tree leaf and dendrobe, selecting, cleaning, airing, and drying until the water content is at most 3%; respectively pulverizing the dragon tree leaf and dendrobe with a coarse pulverizer, and passing through a 100-140-mesh screen; pulverizing the dragon tree leaf coarse powder by a jet mill to obtain the ultrafine powder with the particle size of 10-15 mu m, and pulverizing the dendrobe coarse powder by a vibromill to obtain the ultrafine powder with the particle size of 6-12 mu m; and evenly mixing the 45-55 parts by weight of dragon tree leaf ultrafine powder and the 45-55 parts by weight of dendrobe ultrafine powder. The preparation is prepared by adding pharmaceutically acceptable auxiliary materials into the pharmaceutical composition. The pharmaceutical composition can be used for preparing medicines for treating hyperplasia of mammary glands and diabetes, and has the characteristics of high bioavailability, high active component leaching speed and favorable drug absorption effect.

The present invention relates to novel compounds of formulae I and II and therapeutically acceptable salts thereof, their pharmaceutical compositions processes for making them and their use in therapeutic methods for treatment and/or prevention of various diseases. In particular, the invention relates to compounds which interfere with γ-secretase and/or its substrate and hence modulate the formation of Aβ peptides.

The invention identifies low-expression microRNA (miR-146a) in RA (rheumatoid arthritis) inflammatory cells and confirms that the miR-146a has the effects of inhibiting RA synovial fibroblasts (RASFs)and inflammation.

The invention discloses low-sweetness energy slow-release peanut sugar and a preparation method of the low-sweetness energy slow-release peanut sugar. The low-sweetness energy slow-release peanut sugar comprises the following ingredients in parts by weight through the steps of sugar boiling, stirring, milling and forming: 70 to 90 parts of peeled peanut kernels and sesame, 30 to 60 parts of isomaltulose, 5 to 20 parts of pure water, 0 to 20 parts of cane sugar, 20 to 60 parts of high maltose syrup, 1 t o 5 parts modified starch, 0.5 to 2 parts of edible oil and 0.1 to 0.5 part of common salt. The isomaltulose and the high maltose syrup are adopted as major sweetening agent resources, and the product sweetness is greatly reduced, so the product has the characteristics of agreeable sweetness, crystal and loose structures and melt-in-the-mouth texture, in addition, the great fluctuation of the blood sugar cannot be easily caused by the product, the sugar content is lower than 40 percent, the sweetness is reduced by 40 percent though being compared with that of the traditional peanut sugar, saprodontia can be reduced, and the continuous and slow energy release can be realized.

The invention discloses an application of oxyresveratrol in preparing an ovary aging resistant medicine. The oxyresveratrol has significant treatment effects on various ovary aging diseases such as polycystic ovarian syndrome, dysfunctional uterine bleeding, premature ovarian failure and climacteric syndrome. The oxyresveratrol is prepared into the oral, transdermal or injection medicine for treating the ovary aging diseases.

The invention discloses application of luteolin in preparation of ovarian senescence resistance medicines. The luteolin has obvious effects in treatment of multiple ovarian regression diseases such as polycystic ovarian syndrome, dysfunctional uterine bleeding, premature ovary failure or climacteric syndrome. The luteolin is prepared into oral medicines, transdermal delivery medicines or injection medicines for treating the ovarian regression diseases.

The invention provides an anti-trophoblast cell-surface antigen-2 chimeric antigen receptor, a T cell, preparing method and application thereof. The anti-trophoblast cell-surface antigen-2 chimeric antigen receptor comprises an anti-trophoblast cell-surface antigen-2 scFv antibody, an IgG4 hinge region, a CD28 transmembrane region, a CD3 intracellular region and a 41BB intracellular region. The invention further provides nucleic acid coding the receptor, a carrier comprising the nucleic acid, and a host cell comprising the carrier. The invention further provides a method for utilizing the carrier for transducing the human CD8+/CD4+T cell to obtain a CARTROP2-T cell. The cell is obtained through gene modification and transformation on the T cell. The receptor can be used for treating diseases related to expression of the trophoblast cell-surface antigen-2, and particularly used for specifically recognizing and killing tumors for expressing the trophoblast cell-surface antigen-2.